ConductScience.org, home

Paper16613323

Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.

Aishima S and 6 others. Hum Pathol, 2006. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Papers, record 16613323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16613323

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
PubMed
Journal
Hum Pathol
PubMed
Year
2006
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
0.92
iCite
Revised in PubMed
2019-07-22
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Aishima SShinichi
2Kuroda YYousuke
3Asayama YYoshiki
4Taguchi KKenichi
5Nishihara YYunosuke
6Taketomi AAkinobu
7Tsuneyoshi MMasazumi

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bile Duct NeoplasmsMajor topic
Bile Ducts, IntrahepaticMajor topic
Carcinoma, HepatocellularMajor topic
CholangiocarcinomaMajor topic
Liver NeoplasmsMajor topic
SarcomaMajor topic
Adult
Aged
Biomarkers, Tumor
Disease-Free Survival
Female
Humans
Immunoenzyme Techniques
Male
Middle Aged
Neoplasms, Multiple Primary
Prognosis
Survival Rate

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42374279MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation: a retrospective case series.BMC Med Imaging2026https://conductscience.org/library/papers/42374279PubMed
42226136Combining preoperative clinical and ultrasound radiomic features to predict the predominant component of combined hepatocellular carcinoma-cholangiocarcinoma.BMC Gastroenterol2026https://conductscience.org/library/papers/42226136PubMed
38024583Pathologic features and clinical treatment of sarcomatoid intrahepatic cholangiocarcinoma.Intractable Rare Dis Res2023https://conductscience.org/library/papers/38024583PubMed
30774275Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years.World J Gastroenterol2019https://conductscience.org/library/papers/30774275PubMed
30314525Imaging and clinical features of primary hepatic sarcomatous carcinoma.Cancer Imaging2018https://conductscience.org/library/papers/30314525PubMed
30191007Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.Hepat Oncol2015https://conductscience.org/library/papers/30191007PubMed
29879137The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.PLoS One2018https://conductscience.org/library/papers/29879137PubMed
29856900Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.Cancer Sci2018https://conductscience.org/library/papers/29856900PubMed
29667093The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.J Gastrointest Surg2018https://conductscience.org/library/papers/29667093PubMed
29619266Intrahepatic Sarcomatous Cholangiocarcinoma: Case Report and Review of the Literature.Case Rep Surg2018https://conductscience.org/library/papers/29619266PubMed
27552844Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.Chin J Cancer2016https://conductscience.org/library/papers/27552844PubMed
27161394Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiation.J Hepatobiliary Pancreat Sci2016https://conductscience.org/library/papers/27161394PubMed
25253966Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.World J Gastroenterol2014https://conductscience.org/library/papers/25253966PubMed
21333016Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.BMC Cancer2011https://conductscience.org/library/papers/21333016PubMed
20454704Intrahepatic sarcomatoid cholangiocarcinoma.J Oncol2010https://conductscience.org/library/papers/20454704PubMed
19763713Combined hepatocellular and cholangiocarcinoma with sarcomatoid transformation: radiologic-pathologic correlation of a case.Hepatol Int2009https://conductscience.org/library/papers/19763713PubMed
17072946Hepatic progenitor cells in human liver tumor development.World J Gastroenterol2006https://conductscience.org/library/papers/17072946PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16613323

GET https://conductscience.org/api/papers/v1/16613323/authors